Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Buy" by Analysts

Key Points

• Analysts maintain a bullish view: Eleven firms give Amylyx Pharmaceuticals an average “Buy” rating, including eight buys and two strong buys, with an average 12-month price target of $36.50.
• Several analysts recently raised their price targets, including Robert W. Baird to $52, Mizuho to $42 and Guggenheim to $57, while Wolfe Research upgraded the stock to “strong buy.”
• AMLX opened at $34.10, near its $41.14 12-month high, but the company reported a quarterly adjusted loss of $0.39 per share, missing consensus by $0.03; analysts expect a full-year loss of $1.48 per share.

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have been given an average rating of "Buy" by the eleven research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $36.50.

A number of equities research analysts recently issued reports on the stock. Wolfe Research upgraded shares of Amylyx Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 17th. Robert W. Baird raised their target price on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an "outperform" rating in a report on Wednesday, August 19th. Mizuho boosted their price target on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 18th. Citigroup upped their price target on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Finally, Guggenheim raised their price objective on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a "buy" rating in a research note on Thursday, August 27th.

Insider Transactions at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider directly owned 194,090 shares in the company, valued at approximately $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.90% of the stock is owned by company insiders.

Institutional Trading of Amylyx Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Corient Private Wealth LP bought a new position in Amylyx Pharmaceuticals in the 2nd quarter worth approximately $1,065,000. California State Teachers Retirement System grew its stake in shares of Amylyx Pharmaceuticals by 2,106.9% in the second quarter. California State Teachers Retirement System now owns 1,434,501 shares of the company's stock worth $25,764,000 after acquiring an additional 1,369,499 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Amylyx Pharmaceuticals during the second quarter worth $18,912,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Amylyx Pharmaceuticals by 10.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 173,407 shares of the company's stock valued at $3,114,000 after purchasing an additional 16,318 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its holdings in Amylyx Pharmaceuticals by 27.5% in the 2nd quarter. Hsbc Holdings PLC now owns 14,554 shares of the company's stock valued at $269,000 after purchasing an additional 3,140 shares during the period. Institutional investors and hedge funds own 95.84% of the company's stock.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX opened at $34.10 on Monday. The firm has a market cap of $3.80 billion, a PE ratio of -23.85 and a beta of -0.13. The firm's 50 day moving average price is $24.23 and its 200 day moving average price is $18.21. Amylyx Pharmaceuticals has a twelve month low of $9.75 and a twelve month high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, sell-side analysts anticipate that Amylyx Pharmaceuticals will post -1.48 earnings per share for the current fiscal year.

About Amylyx Pharmaceuticals

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source